This is an unofficial archive of PsychonautWiki as of 2025-08-11T15:14:44Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.
1B-LSD: Difference between revisions
>Azed Removed a faulty link |
>Utaninja →Subjective effects: 1p lsd page has same message without a citation needed |
||
| (2 intermediate revisions by 2 users not shown) | |||
| Line 2: | Line 2: | ||
{{SubstanceBox/1B-LSD}} | {{SubstanceBox/1B-LSD}} | ||
'''1-Butanoyl-''d''-lysergic acid diethylamide''' (also known as '''1B-LSD''') is a novel [[Psychoactive class::psychedelic]] substance of the [[Chemical class::lysergamide]] class. | '''1-Butanoyl-''d''-lysergic acid diethylamide''' (also known as '''1B-LSD''') is a novel [[Psychoactive class::psychedelic]] substance of the [[Chemical class::lysergamide]] class. | ||
1B-LSD is closely related to [[LSD]] and [[1P-LSD]] and is reported to produce near-identical effects. 1B-LSD has been found to be around 14% as potent as LSD and expresses itself at the same 5-HT<sub>2A</sub> receptor.<ref name=":0">Brandt, | 1B-LSD is closely related to [[LSD]] and [[1P-LSD]] and is reported to produce near-identical effects. 1B-LSD has been found to be around 14% as potent as LSD and expresses itself at the same 5-HT<sub>2A</sub> receptor.<ref name=":0">{{cite journal | vauthors=((Brandt, S. D.)), ((Kavanagh, P. V.)), ((Westphal, F.)), ((Stratford, A.)), ((Elliott, S. P.)), ((Dowling, G.)), ((Wallach, J.)), ((Halberstadt, A. L.)) | journal=Drug Testing and Analysis | title=Return of the lysergamides. Part V: Analytical and behavioural characterization of 1‐butanoyl‐ d ‐lysergic acid diethylamide (1B‐LSD) | volume=11 | issue=8 | pages=1122–1133 | date= August 2019 | url=https://onlinelibrary.wiley.com/doi/10.1002/dta.2613 | issn=1942-7603 | doi=10.1002/dta.2613}}</ref> | ||
The original synthesis date of 1B-LSD is not known. Unlike most [[research chemicals]], 1B-LSD has no prior record in the scientific literature. The first reports of 1B-LSD use surfaced in 2018 following its appearance on the online [[research chemical]] market. | The original synthesis date of 1B-LSD is not known. Unlike most [[research chemicals]], 1B-LSD has no prior record in the scientific literature. The first reports of 1B-LSD use surfaced in 2018 following its appearance on the online [[research chemical]] market. | ||
[[Subjective effects]] include [[visual geometry]], [[hallucinatory states]], [[time distortion]], [[introspection|enhanced introspection]], [[conceptual thinking]], [[increased music appreciation]], [[euphoria]], and [[ego loss]]. User reports indicate that the subjective effects of 1B-LSD are extremely similar to those of 1P-LSD. 1B-LSD acts as a prodrug for LSD.<ref name=":1">Wagmann, | [[Subjective effects]] include [[visual geometry]], [[hallucinatory states]], [[time distortion]], [[introspection|enhanced introspection]], [[conceptual thinking]], [[increased music appreciation]], [[euphoria]], and [[ego loss]]. User reports indicate that the subjective effects of 1B-LSD are extremely similar to those of 1P-LSD. 1B-LSD acts as a [[prodrug]] for LSD.<ref name=":1">{{cite journal | vauthors=((Wagmann, L.)), ((Richter, L. H. J.)), ((Kehl, T.)), ((Wack, F.)), ((Bergstrand, M. P.)), ((Brandt, S. D.)), ((Stratford, A.)), ((Maurer, H. H.)), ((Meyer, M. R.)) | journal=Analytical and Bioanalytical Chemistry | title=In vitro metabolic fate of nine LSD-based new psychoactive substances and their analytical detectability in different urinary screening procedures | volume=411 | issue=19 | pages=4751–4763 | date= July 2019 | url=http://link.springer.com/10.1007/s00216-018-1558-9 | issn=1618-2642 | doi=10.1007/s00216-018-1558-9}}</ref> The similarities in chemical structure between 1B-LSD and [[LSD]] predicts a near-identical effect profile, likely differing mainly in its rate of absorption and duration. | ||
Very little data exists about the pharmacological properties, metabolism, and toxicity of 1B-LSD. It is presumed to have a similar toxicity and risk profile as [[LSD]], although no evidence currently exists to support this. It is highly advised to use [[harm reduction practices]] if using this substance. | Very little data exists about the pharmacological properties, metabolism, and toxicity of 1B-LSD. It is presumed to have a similar toxicity and risk profile as [[LSD]], although no evidence currently exists to support this. It is highly advised to use [[harm reduction practices]] if using this substance. | ||
| Line 30: | Line 30: | ||
==Subjective effects== | ==Subjective effects== | ||
Anecdotal reports from many users suggest that the subjective effects of 1B-LSD are so similar to that of [[LSD]] so as to be virtually indistinguishable from one another. In comparison to other psychedelics such as [[psilocybin]], [[LSA]] and [[ayahuasca]], 1B-LSD is significantly more stimulating and fast-paced regarding the specific style of its physical and cognitive effects. | Anecdotal reports from many users suggest that the subjective effects of 1B-LSD are so similar to that of [[LSD]] so as to be virtually indistinguishable from one another. In comparison to other psychedelics such as [[psilocybin]], [[LSA]] and [[ayahuasca]], 1B-LSD is significantly more stimulating and fast-paced regarding the specific style of its physical and cognitive effects. | ||
{{Preamble/SubjectiveEffects}} | {{Preamble/SubjectiveEffects}} | ||
| Line 199: | Line 199: | ||
*'''Switzerland''': 1B-LSD can be considered a controlled substance as a defined derivative of Lysergic Acid under Verzeichnis E point 263. It is legal when used for scientific or industrial use.<ref>{{cite web|url=https://www.admin.ch/opc/de/classified-compilation/20101220/index.html|title=Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien|publisher=Bundeskanzlei [Federal Chancellery of Switzerland]|access-date=January 1, 2020|language=de}}</ref> | *'''Switzerland''': 1B-LSD can be considered a controlled substance as a defined derivative of Lysergic Acid under Verzeichnis E point 263. It is legal when used for scientific or industrial use.<ref>{{cite web|url=https://www.admin.ch/opc/de/classified-compilation/20101220/index.html|title=Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien|publisher=Bundeskanzlei [Federal Chancellery of Switzerland]|access-date=January 1, 2020|language=de}}</ref> | ||
*'''United Kingdom''': 1B-LSD is illegal to produce, supply, or import under the Psychoactive Substance Act, which came into effect on May 26, 2016.<ref>{{cite web|url=http://www.legislation.gov.uk/ukpga/2016/2/contents/enacted|title=Psychoactive Substances Act 2016|access-date=January 1, 2020|publisher=UK Government}}</ref> | *'''United Kingdom''': 1B-LSD is illegal to produce, supply, or import under the Psychoactive Substance Act, which came into effect on May 26, 2016.<ref>{{cite web|url=http://www.legislation.gov.uk/ukpga/2016/2/contents/enacted|title=Psychoactive Substances Act 2016|access-date=January 1, 2020|publisher=UK Government}}</ref> | ||
*'''United States''': While 1B-LSD is not explicitly prohibited by law it is however, a prodrug for LSD, meaning its possession and sale may be prosecutable in the United States under the Federal Analogue Act.<ref>21 U.S. Code § 813 https://www.law.cornell.edu/uscode/text/21/813</ref> | *'''United States''': While 1B-LSD is not explicitly prohibited by law it is however, a prodrug for LSD, meaning its possession and sale may be prosecutable in the United States under the Federal Analogue Act.<ref>{{Citation | title=21 U.S. Code § 813 - Treatment of controlled substance analogues | url=https://www.law.cornell.edu/uscode/text/21/813}}</ref> | ||
==See also== | ==See also== | ||